Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEGEND-2: LCAR-B38M in r/r Multiple Myeloma
NCT03090659Phase 2Unknown
- Sponsor
- Legend Biotech Corporation
- Start
- Oct 2015
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 2, open-label, single-arm trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Legend Biotech Corporation. Primary endpoint: Occurrence of treatment related adverse events. Status: unknown.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03090659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03090659.